Key facts
- MARS Bioimaging’s last known valuation is $5.8M (Feb 2014).
- It has raised $16.3M; the latest was Later Stage VC ($15.0M) in Jan 2026.
- Notable investors include Enterprise Angels, Aspire NZ Seed Fund, Booster Innovation Fund, Cure Kids Ventures, Flying Kiwi Angels — 11 tracked in total.
- MARS Bioimaging has filed 1 Form D with the SEC, most recently Jun 2018 ( sold).
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for MARS Bioimaging
- ·The full record, as it builds
Funding rounds
No funding rounds for MARS Bioimaging are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MARS Bioimaging
Manufacturer of small-bore spectral CT scanners intended to offer pre-clinical medical research. The company's scanners work closely with customers to provide a wide range of spectral imaging solutions for applications ranging from cancer detection to the development of novel contrast agents, enabling customers to conduct experiments in a system that is directly translatable to human imaging.
- Sector
- Healthcare
- HQ
- Christchurch, New Zealand
- Founded
- 2002
- Employees
- 22
- Website
- marsbioimaging.com/
- Ownership
- Privately Held (backing)
MARS Bioimaging doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MARS Bioimaging shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MARS Bioimaging in its N-PORT filings yet. We sweep new filings monthly.